[go: up one dir, main page]

WO2005034978A3 - MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF - Google Patents

MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF Download PDF

Info

Publication number
WO2005034978A3
WO2005034978A3 PCT/EP2004/010994 EP2004010994W WO2005034978A3 WO 2005034978 A3 WO2005034978 A3 WO 2005034978A3 EP 2004010994 W EP2004010994 W EP 2004010994W WO 2005034978 A3 WO2005034978 A3 WO 2005034978A3
Authority
WO
WIPO (PCT)
Prior art keywords
ikk
epsiv
inhibitors
medical use
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/010994
Other languages
French (fr)
Other versions
WO2005034978A2 (en
Inventor
Christian Korherr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xantos Biomedicine AG
Original Assignee
Xantos Biomedicine AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xantos Biomedicine AG filed Critical Xantos Biomedicine AG
Publication of WO2005034978A2 publication Critical patent/WO2005034978A2/en
Publication of WO2005034978A3 publication Critical patent/WO2005034978A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel angiogenic factor, IKKϵ, as well as to inhibitors thereof and to their use in pharmaceutical or diagnostic compositions.
PCT/EP2004/010994 2003-10-02 2004-10-01 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF Ceased WO2005034978A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810003P 2003-10-02 2003-10-02
US60/508,100 2003-10-02

Publications (2)

Publication Number Publication Date
WO2005034978A2 WO2005034978A2 (en) 2005-04-21
WO2005034978A3 true WO2005034978A3 (en) 2005-06-23

Family

ID=34434896

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2004/010996 Ceased WO2005035746A2 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof
PCT/EP2004/010994 Ceased WO2005034978A2 (en) 2003-10-02 2004-10-01 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010996 Ceased WO2005035746A2 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof

Country Status (3)

Country Link
EP (1) EP1670908A2 (en)
CA (1) CA2540775A1 (en)
WO (2) WO2005035746A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080052650A (en) * 2005-09-07 2008-06-11 라보라토리스 세로노 에스.에이. Ikk inhibitors for the treatment of endometriosis
JP5934093B2 (en) 2009-07-24 2016-06-15 ジアディック・バイオテック・アグルパシオン・デ・インテレス・エコノミコＧｅａｄｉｃ Ｂｉｏｔｅｃ， Ａｉｅ． Markers for endometrial cancer
GB201114051D0 (en) * 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
WO2015070027A1 (en) * 2013-11-07 2015-05-14 University Of Southern California Use of ikk epsilon inhibitors to activate nfat and t cell response

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039308A1 (en) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Ikk3 kinase
WO2002028999A2 (en) * 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
US20030050270A1 (en) * 1998-11-20 2003-03-13 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-beta expression
US20030092654A1 (en) * 1998-11-20 2003-05-15 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-alpha expression
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2004001008A2 (en) * 2002-06-21 2003-12-31 Incyte Corporation Kinases and phosphatases
WO2004097009A2 (en) * 2003-05-01 2004-11-11 Novartis Ag METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837514A (en) * 1997-03-07 1998-11-17 Tularik Inc. IκB kinases
CA2327351A1 (en) * 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Cell signaling proteins
EP1019513A1 (en) * 1998-08-04 2000-07-19 Immunex Corporation Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases
GB9929542D0 (en) * 1999-12-14 2000-02-09 Glaxo Wellcome Kk Ikk4
US20030232771A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of MARK3 expression
WO2004012673A2 (en) * 2002-08-01 2004-02-12 Wyeth, Methods and reagents relating to inflammation and apoptosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050270A1 (en) * 1998-11-20 2003-03-13 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-beta expression
US20030092654A1 (en) * 1998-11-20 2003-05-15 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-alpha expression
WO2000039308A1 (en) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Ikk3 kinase
WO2002028999A2 (en) * 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2004001008A2 (en) * 2002-06-21 2003-12-31 Incyte Corporation Kinases and phosphatases
WO2004097009A2 (en) * 2003-05-01 2004-11-11 Novartis Ag METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAVCHENKO V V ET AL: "IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 29, 18 July 2003 (2003-07-18), pages 26612 - 26619, XP002297127, ISSN: 0021-9258 *
LUDBROOK V. ET AL.: "Characterisation of IkapaB Kinase 3 in cells involved in rheumatoid arthritis", INFLAMMATION RESEARCH, vol. 52, July 2003 (2003-07-01), XP009046287 *
YEMELYANOV A. ET AL.: "IKKi is a component of the positive feedback loop involved in the constitutive activation of NF-kappaB in prostate carcinoma cells", PROC. AMERIC. ASSOC. FOR CANCER RESEARCH, vol. 44, July 2003 (2003-07-01), pages 852, XP001206089 *

Also Published As

Publication number Publication date
EP1670908A2 (en) 2006-06-21
WO2005034978A2 (en) 2005-04-21
WO2005035746A3 (en) 2005-06-23
CA2540775A1 (en) 2005-04-21
WO2005035746A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
EP2415760A3 (en) CCR-9 antagonists
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
WO2004041269A3 (en) New use for pharmaceutical composition
EP2500438A3 (en) Novel compositions and methods for the treatment of psoriasis
WO2005019256A3 (en) Muteins of tear lipocalin
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005039663A3 (en) Alloy compositions and devices including the compositions
WO2002092026A3 (en) Dermatological and cosmetic compositions
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2009029049A8 (en) A bone and/or dental cement composition and uses thereof
EP2540301A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
TW200505875A (en) Novel compounds
WO2003053394A3 (en) Use of apple core extracts in cosmetic or pharmaceutical co mpositions
WO2005054244A3 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis
EP2017620A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
WO2005041881A3 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2005034978A3 (en) MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
WO2002089740A3 (en) Sulfonamides
NO20054346L (en) Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions
WO2004043366A3 (en) Sulfonamides
WO2004080379A3 (en) Extract of pangium edule and lignanes which can be used as a cathepsin inhibitor or having an antinecrotic effect
WO2004072037A8 (en) 2,3'-bipyridines derivatives as selective cox-2 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase